Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC

NCT ID: NCT02808390

Last Updated: 2018-11-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-28

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 2 doses of GED-0507-34-Levo in subjects with active, mild-to-moderate UC.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 2, Proof of Concept, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 2 doses of GED-0507-34-Levo in subjects with active, mild-to-moderate Ulcerative Colitis.

The study will consist of 3 phases:

* Screening Phase - up to 4 weeks
* Double-blind Placebo-controlled Phase - Weeks 0 to 8
* Follow-up Phase - Week 9

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

80 mg BID

GED-0507-34-Levo 80 mg BID for 8 Weeks

Group Type EXPERIMENTAL

GED-0507-34-Levo 80 mg

Intervention Type DRUG

GED-0507-34-Levo 80 mg BID for 8 Weeks

160 mg BID

GED-0507-34-Levo 160 mg BID for 8 Weeks

Group Type EXPERIMENTAL

GED-0507-34-Levo 160 mg

Intervention Type DRUG

GED-0507-34-Levo 160 mg BID for 8 Weeks

Placebo

Placebo BID for 8 Weeks

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Placebo BID for 8 Weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GED-0507-34-Levo 80 mg

GED-0507-34-Levo 80 mg BID for 8 Weeks

Intervention Type DRUG

GED-0507-34-Levo 160 mg

GED-0507-34-Levo 160 mg BID for 8 Weeks

Intervention Type DRUG

Placebo

Placebo BID for 8 Weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged 18 and over at the time of signing the informed consent.
* Diagnosis of UC with a duration of at least 3 months prior to the Screening Visit.
* MMS ≥ 4 to ≤ 8 (range: 0 - 9) prior to randomization in the study
* Subjects are required to have a colonoscopy if one has not been performed within 12 months prior to the Screening Visit.
* Subjects who have relapsed on maintenance therapy with doses of 5-ASA ≤ 2.4 g/day

Exclusion Criteria

* Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis, or diverticular disease-associated colitis.
* UC restricted to the distal 15 cm or less (eg, ulcerative proctitis).
* Subjects who have had surgery as a treatment for UC or who, in the opinion of the Investigator, are likely to require surgery for UC during the study.
* Clinical signs suggestive of fulminant colitis or toxic megacolon.
* Evidence of pathogenic enteric infection.
* History of colorectal cancer or colorectal dysplasia.
* Prior use of any TNF inhibitor (or any biologic agent).
* Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine, or thalidomide.
* Use of budesonide-MMx within the last 8 weeks.
* Use of oral and/or IV corticosteroids within 2 weeks of the Screening Visit.
* Use of immunosuppressants (azathioprine \[AZA\], 6-mercaptopurine \[6-MP\] or methotrexate \[MTX\]) within 8 weeks of the Screening Visit.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

PPM Services S.A.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Applications Laboratories, Inc.

San Diego, California, United States

Site Status

Center for Advanced Gastroenterology, PLLC

Maitland, Florida, United States

Site Status

Advanced Research Institute, Inc.

New Port Richey, Florida, United States

Site Status

IMIC, Inc

Palmetto Bay, Florida, United States

Site Status

BRCR Medical Center, Inc

Pembroke Pines, Florida, United States

Site Status

Mount Sinai

New York, New York, United States

Site Status

Penn State University Milton S. Hershey Medical Center

State College, Pennsylvania, United States

Site Status

Texas Clinical Research Institute, LLC

Arlington, Texas, United States

Site Status

Cook Children's Medical Center

Fort Worth, Texas, United States

Site Status

Envision Clinical Research, LLC

Laredo, Texas, United States

Site Status

Sagact, Pllc

San Antonio, Texas, United States

Site Status

Medical Centre "Asklepii", OOD

Dupnitsa, , Bulgaria

Site Status

MHAT - Pazardzhik AD

Pazardzhik, , Bulgaria

Site Status

UMHAT "Sv. Georgi", EAD

Plovdiv, , Bulgaria

Site Status

MHAT "Sv. Karidad", EAD

Plovdiv, , Bulgaria

Site Status

MHAT - Silistra AD

Silistra, , Bulgaria

Site Status

MHAT "Sv. Petka" - Vidin, AD

Vidin, , Bulgaria

Site Status

Brandon Medical Arts Clinic

Brandon, Manitoba, Canada

Site Status

Humber River Hospital

Toronto, Ontario, Canada

Site Status

CHU Amiens - Hopital Sud, Service d'Hépato-Gastroentérologie

Amiens, , France

Site Status

Cabinet Médical de Gastro-entérologie Dr.Lesage

Armentières, , France

Site Status

Hôpital Claude Huriez - CHU Lille, Service des maladies de l'appareil digestif

Lille, , France

Site Status

Cabinet Médical de Gastroentérologie Dr. Bismuth

Lille, , France

Site Status

Cabinet Médical de Gastroentérologie Dr. Ben Ali

Roubaix, , France

Site Status

Cabinet Médical de Gastro-entérologie Dr.Vernier Massouille

Tourcoing, , France

Site Status

Principal SMO Kft.

Baja, , Hungary

Site Status

Semmelweis Egyetem

Budapest, , Hungary

Site Status

Endomedix Diagnosztikai Kozpont

Budapest, , Hungary

Site Status

Debreceni Egyetem Klinikai Kozpont

Debrecen, , Hungary

Site Status

Bugat Pal Korhaz, Gasztroenterologia

Gyöngyös, , Hungary

Site Status

Somogy Megyei Kaposi Mor Oktato Korhaz, Gastroenterologiai Osztaly

Kaposvár, , Hungary

Site Status

Mazso-Pharma Kutatasfejlesztesi Kft

Szeged, , Hungary

Site Status

Fondazione IRCCS Ospedale Maggiore, Policlinico Mangiagalli e Regina Elena. Dipartimento di Medicina e Specialità Mediche

Milan, , Italy

Site Status

Fondazione IRCCS Policlinico San Matteo

Pavia, , Italy

Site Status

Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Dipartimento di Medicina Interna

Roma, , Italy

Site Status

Policlinico Universitario Agostino Gemelli, UOC Medicina Interna e gastroenterologia - CIC

Rome, , Italy

Site Status

Polana D LLC

Daugavpils, , Latvia

Site Status

J.Seleznovs Doctor Practice

Jelgava, , Latvia

Site Status

Health Center 4, Affiliate Diagnostic Center

Riga, , Latvia

Site Status

Riga East Clinical University Hospital

Riga, , Latvia

Site Status

Pauls Stradins Clinical University Hospital SLLC

Riga, , Latvia

Site Status

Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS

Leszno, , Poland

Site Status

Korczowski Bartosz, Gabinet Lekarski, Private Pediatric Office

Rzeszów, , Poland

Site Status

Niepubliczny Zaklad Opieki Zdrowotnej SONOMED

Szczecin, , Poland

Site Status

Centrum Zdrowia Matki, Dziecka i Mlodziezy

Warsaw, , Poland

Site Status

Ars-Medica S.C Rybak Maria, Rybak Zbigniew

Wroclaw, , Poland

Site Status

Alian s.r.o.

Bardejov, , Slovakia

Site Status

B+B MED, s.r.o., Gastroenterologicka ambulancia, MUDr. Brandeburova

Košice, , Slovakia

Site Status

Gastromedic, s.r.o

Nové Zámky, , Slovakia

Site Status

Med Center of Eurolab LLC Policlinic Outpatient Dept O.O.Bogomolets NMU

Kyiv, , Ukraine

Site Status

CI of Kyiv RC Kyiv Regional Clinical Hospital

Kyiv, , Ukraine

Site Status

Lviv Regional Clinical Hospital D.Halytskyi Lviv NMU

Lviv, , Ukraine

Site Status

Lviv Municipal City Clinical Hospital #5 Dept of Therapy D.Halytsky Lviv NMU

Lviv, , Ukraine

Site Status

CI Odesa Regional Clinical Hospital, Center of Gastroenterology

Odesa, , Ukraine

Site Status

CI of SRC Sumy RCH Dept of Gasroenterology Sumy SU MI,Chair of Internal Medicine of PGE

Sumy, , Ukraine

Site Status

A. Novak Transcarpathian Regional Clinical Hospital

Uzhhorod, , Ukraine

Site Status

Vinnytsya RCH for Patriotic War Invalides Therapeutic Dept # 1 Vinnytsia M.I.Pyrogov NMU

Vinnytsia, , Ukraine

Site Status

CI City Clinical Hospital #6 Dept of Gastroenterology

Zaporizhzhia, , Ukraine

Site Status

CI City Hospital #1, Dept of Surgery

Zaporizhzhia, , Ukraine

Site Status

CI Zaporizhzhia Regional Clinical Hospital of ZRC

Zaporizhzhia, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Canada France Hungary Italy Latvia Poland Slovakia Ukraine

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GED0507-UC-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.